{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T16:12:12Z","timestamp":1779034332288,"version":"3.51.4"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.01618","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T05:58:49Z","timestamp":1579067929000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder"],"prefix":"10.3389","volume":"10","author":[{"given":"Qin-Qin","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Qiong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Yan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1590\/S1677-5538.IBJU.2014.0221","article-title":"Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder","volume":"41","author":"Abdelwahab","year":"2015","journal-title":"Int. Braz. J. Urol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1067\/mob.2002.125704","article-title":"The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society","volume":"187","author":"Abrams","year":"2002","journal-title":"Am. J. Obstet. Gynecol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4103\/0974-7796.82170","article-title":"Prospective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder","volume":"3","author":"Altaweel","year":"2011","journal-title":"Urol. Ann."},{"key":"B4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000339600","article-title":"An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity","volume":"89","author":"Asimakopoulos","year":"2012","journal-title":"Urol. Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","article-title":"Refractory idiopathic urge urinary incontinence and botulinum A injection","volume":"180","author":"Brubaker","year":"2008","journal-title":"J. Urol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur. Urol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/nau.22395","article-title":"The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients","volume":"33","author":"Chen","year":"2014","journal-title":"Neurourol. Urodyn."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0159307","DOI":"10.1371\/journal.pone.0159307","article-title":"Efficacy and safety of OnabotulinumtoxinA in patients with neurogenic detrusor overactivity: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Cheng","year":"2016","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/nau.20611","article-title":"Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units","volume":"28","author":"Cohen","year":"2009","journal-title":"Neurourol. Urodyn."},{"key":"B10","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur. Urol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1159\/000351037","article-title":"Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis","volume":"91","author":"Cui","year":"2013","journal-title":"Urol. Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/nau.22598","article-title":"The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: a systematic review and meta-analysis","volume":"34","author":"Cui","year":"2015","journal-title":"Neurourol. Urodyn."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/sim.1188","article-title":"Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes","volume":"21","author":"Deeks","year":"2002","journal-title":"Stat. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","article-title":"Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study","volume":"61","author":"Denys","year":"2012","journal-title":"Eur. Urol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J. Urol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/nau.23513","article-title":"The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age-related comorbidities in the United States","volume":"37","author":"Durden","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"B17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12894-015-0102-x","article-title":"Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series","volume":"15","author":"Engeler","year":"2015","journal-title":"BMC Urol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1097\/01.ju.0000143889.00681.3f","article-title":"The effect of botulinum-A toxin on patients with severe urge urinary incontinence","volume":"172","author":"Flynn","year":"2004","journal-title":"J. Urol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1517\/14656566.3.7.827","article-title":"Current pharmacotherapeutic strategies for overactive bladder","volume":"3","author":"Garely","year":"2002","journal-title":"Expert Opin. Pharmacother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","article-title":"Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity","volume":"187","author":"Ginsberg","year":"2012","journal-title":"J. Urol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s12325-013-0054-z","article-title":"OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology","volume":"30","author":"Ginsberg","year":"2013","journal-title":"Adv. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J. Urol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"90338","DOI":"10.18632\/oncotarget.20056","article-title":"A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages","volume":"8","author":"Gu","year":"2017","journal-title":"Oncotarget."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1016\/j.juro.2011.02.004","article-title":"Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial","volume":"185","author":"Herschorn","year":"2011","journal-title":"J. Urol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/1469-0691.12494","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins JP","year":"2002","journal-title":"Stat. Med."},{"key":"B26","volume-title":"Cochrane handbook for systematic reviews of interventions, v.5.1","author":"Higgins JP","year":"2011"},{"key":"B28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.urology.2012.11.010","article-title":"Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis","volume":"81","author":"Kennelly","year":"2013","journal-title":"Urology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/nau.20105","article-title":"Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity","volume":"24","author":"Kessler","year":"2005","journal-title":"Neurourol. Urodyn."},{"key":"B30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/21681805.2015.1121406","article-title":"Intravesical instillation of onabotulinum toxin A embedded in inert hydrogel in the treatment of idiopathic overactive bladder: A double-blind randomized pilot study","volume":"50","author":"Krhut","year":"2016","journal-title":"Scand. J. Urol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.urology.2005.02.002","article-title":"Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics","volume":"66","author":"Kuo","year":"2005","journal-title":"Urol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/AOG.0b013e3181660c1b","article-title":"Prevalence and co-occurrence of pelvic floor disorders in community-dwelling women","volume":"111","author":"Lawrence","year":"2008","journal-title":"Obstet. Gynecol."},{"key":"B33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.curobgyn.2004.07.004","article-title":"Detrusor overactivity","volume":"14","author":"Majumdar","year":"2004","journal-title":"Curr. Obstet. Gynaecol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.apmr.2013.04.011","article-title":"Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury","volume":"94","author":"Mehta","year":"2013","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"B35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/1469-0691.12494","article-title":"The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses","volume":"20","author":"Melsen","year":"2014","journal-title":"Clin. Microbiol. Infect.: Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J. Urol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.urology.2014.07.046","article-title":"Incidence of adverse events after high doses of onabotulinumtoxinA for multiple indications","volume":"84","author":"Nuanthaisong","year":"2014","journal-title":"Urol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1097\/01.ju.0000169480.43557.31","article-title":"A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin","volume":"174","author":"Popat","year":"2005","journal-title":"J. Urol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/j.1464-410X.2005.05725.x","article-title":"A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity","volume":"96","author":"Rajkumar","year":"2005","journal-title":"BJU Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/nau.21021","article-title":"Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder","volume":"30","author":"Rovner","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/nau.22376","article-title":"OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity","volume":"32","author":"Rovner","year":"2013","journal-title":"Neurourol. Urodyn."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","article-title":"Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial","volume":"177","author":"Sahai","year":"2007","journal-title":"J. Urol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0022-5347(06)00590-8","article-title":"Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics","volume":"176","author":"Schmid","year":"2006","journal-title":"J. Urol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.eururo.2005.06.021","article-title":"Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction","volume":"48","author":"Schulte-Baukloh","year":"2005","journal-title":"Eur. Urol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","article-title":"Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study","volume":"174","author":"Schurch","year":"2005","journal-title":"J. Urol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/ijcp.12443","article-title":"OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder","volume":"68","author":"Sievert","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"B48","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J. Urol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s11255-015-1125-7","article-title":"The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis","volume":"47","author":"Sun","year":"2015","journal-title":"Int. Urol. Nephrol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ogc.2015.10.002","article-title":"Overactive Bladder","volume":"43","author":"White","year":"2016","journal-title":"Obstet. Gynecol. Clin. North Am."},{"key":"B51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1590\/S1677-5538.IBJU.2015.02.05","article-title":"OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review","volume":"41","author":"Zhang","year":"2015","journal-title":"Int. Braz. J. Urol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"963","DOI":"10.4103\/0366-6999.154318","article-title":"Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis","volume":"128","author":"Zhou","year":"2015","journal-title":"Chin. Med. J. (Engl)."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01618\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T05:58:52Z","timestamp":1579067932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.01618\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":52,"alternative-id":["10.3389\/fphar.2019.01618"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.01618","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737896976.793577811","asserted-by":"object"}]},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,15]]},"article-number":"1618"}}